NASDAQ · GOSS

Gossamer Bio, Inc.

Healthcare · Biotechnology

$9.28

Up+$0.67 (+7.22%)

Updated Nov 4, 2026, 9:34 PM

SID Score

6.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap: 824.25M
P/E ratio: -5.95
Dividend yield: 0.00%
52-week range: $0.11 – $14.75
Volume: 139.46K
Avg. volume: 3.24M

Price performance · GOSS

GOSS price history

1M range · 0 trading sessions · Daily adjusted prices

Data unavailable

Market data is busy. Please try again shortly.

Latest GOSS news

The latest Smart Investors Daily articles mentioning GOSS.

analystOct 26, 2026

Chardan Capital Reiterates Buy Rating on Gossamer Bio, Inc. (GOSS)

analystOct 14, 2026

Chardan Capital Initiates Coverage on Gossamer Bio, Inc. (GOSS) with Buy

priceOct 13, 2026

Gossamer Bio, Inc. (GOSS) Surges 5.7% on Heavy Volume

Latest GOSS news

The latest Smart Investors Daily articles mentioning GOSS.

GOSS research

SEC Filings

Recent regulatory filings and source documents.

GOSS SEC filings
Filed	Form	Description	Accepted	Document
Oct 28, 2026	8-K	Form 8-K - Current report - Item 5.07	—	Open source
Sep 28, 2026	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Sep 23, 2026	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Sep 16, 2026	8-K	Form 8-K - Current report - Item 5.02 Item 9.01	—	Open source
Sep 11, 2026	8-K	Form 8-K - Current report - Item 3.03 Item 5.03 Item 8.01 Item 9.01	—	Open source
Sep 9, 2026	8-K	Form 8-K - Current report - Item 8.01 Item 9.01	—	Open source
Sep 3, 2026	8-K	Form 8-K - Current report - Item 5.03 Item 9.01	—	Open source
Aug 26, 2026	8-K	Form 8-K - Current report - Item 5.03 Item 9.01	—	Open source
Aug 21, 2026	8-K	Form 8-K - Current report - Item 1.01 Item 3.02 Item 5.03 Item 7.01 Item 9.01	—	Open source
Aug 13, 2026	8-K	Form 8-K - Current report - Item 2.02 Item 9.01	—	Open source
Jul 27, 2026	8-K	Form 8-K - Current report - Item 1.01 Item 1.02 Item 2.02 Item 7.01 Item 8.01 Item 9.01	—	Open source
Jul 14, 2026	8-K	Form 8-K - Current report - Item 5.02 Item 5.03 Item 5.07 Item 9.01	—	Open source
Jul 1, 2026	8-K	Form 8-K - Current report - Item 7.01 Item 9.01	—	Open source
Jun 17, 2026	8-K	Form 8-K - Current report - Item 7.01 Item 9.01	—	Open source
Apr 9, 2026	8-K	Form 8-K - Current report - Item 3.01	—	Open source
Mar 17, 2026	8-K	Form 8-K - Current report - Item 2.02 Item 9.01	—	Open source
Nov 5, 2025	8-K	Form 8-K - Current report - Item 2.02 Item 9.01	—	Open source
Sep 25, 2025	8-K	Form 8-K - Current report - Item 3.02	—	Open source
Aug 5, 2025	8-K	Form 8-K - Current report - Item 2.02 Item 9.01	—	Open source
Jun 25, 2025	8-K	Form 8-K - Current report - Item 5.02 Item 5.07	—	Open source
Jun 16, 2025	8-K	Form 8-K - Current report - Item 7.01 Item 8.01 Item 9.01	—	Open source
May 15, 2025	8-K	Form 8-K - Current report - Item 2.02 Item 9.01	—	Open source
Mar 13, 2025	8-K	Form 8-K - Current report - Item 2.02 Item 9.01	—	Open source
Feb 19, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Nov 7, 2024	8-K	Form 8-K - Current report - Item 2.02 Item 9.01	—	Open source
Sep 13, 2024	8-K	Form 8-K - Current report - Item 3.01	—	Open source
Aug 12, 2024	8-K	Form 8-K - Current report - Item 2.02 Item 9.01	—	Open source
Jul 18, 2024	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Jun 10, 2024	8-K	Form 8-K - Current report - Item 5.07	—	Open source
May 24, 2024	8-K	Form 8-K - Current report - Item 3.01	—	Open source
May 7, 2024	8-K	Form 8-K - Current report - Item 2.02 Item 9.01	—	Open source

Filed

Form

Description

Accepted

Document

Oct 28, 2026

8-K

Form 8-K - Current report - Item 5.07

—

Open source

Sep 28, 2026

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Sep 23, 2026

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Sep 16, 2026

8-K

Form 8-K - Current report - Item 5.02 Item 9.01

—

Open source

Sep 11, 2026

8-K

Form 8-K - Current report - Item 3.03 Item 5.03 Item 8.01 Item 9.01

—

Open source

Sep 9, 2026

8-K

Form 8-K - Current report - Item 8.01 Item 9.01

—

Open source

Sep 3, 2026

8-K

Form 8-K - Current report - Item 5.03 Item 9.01

—

Open source

Aug 26, 2026

8-K

Form 8-K - Current report - Item 5.03 Item 9.01

—

Open source

Aug 21, 2026

8-K

Form 8-K - Current report - Item 1.01 Item 3.02 Item 5.03 Item 7.01 Item 9.01

—

Open source

Aug 13, 2026

8-K

Form 8-K - Current report - Item 2.02 Item 9.01

—

Open source

Jul 27, 2026

8-K

Form 8-K - Current report - Item 1.01 Item 1.02 Item 2.02 Item 7.01 Item 8.01 Item 9.01

—

Open source

Jul 14, 2026

8-K

Form 8-K - Current report - Item 5.02 Item 5.03 Item 5.07 Item 9.01

—

Open source

Jul 1, 2026

8-K

Form 8-K - Current report - Item 7.01 Item 9.01

—

Open source

Jun 17, 2026

8-K

Form 8-K - Current report - Item 7.01 Item 9.01

—

Open source

Apr 9, 2026

8-K

Form 8-K - Current report - Item 3.01

—

Open source

Mar 17, 2026

8-K

Form 8-K - Current report - Item 2.02 Item 9.01

—

Open source

Nov 5, 2025

8-K

Form 8-K - Current report - Item 2.02 Item 9.01

—

Open source

Sep 25, 2025

8-K

Form 8-K - Current report - Item 3.02

—

Open source

Aug 5, 2025

8-K

Form 8-K - Current report - Item 2.02 Item 9.01

—

Open source

Jun 25, 2025

8-K

Form 8-K - Current report - Item 5.02 Item 5.07

—

Open source

Jun 16, 2025

8-K

Form 8-K - Current report - Item 7.01 Item 8.01 Item 9.01

—

Open source

May 15, 2025

8-K

Form 8-K - Current report - Item 2.02 Item 9.01

—

Open source

Mar 13, 2025

8-K

Form 8-K - Current report - Item 2.02 Item 9.01

—

Open source

Feb 19, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Nov 7, 2024

8-K

Form 8-K - Current report - Item 2.02 Item 9.01

—

Open source

Sep 13, 2024

8-K

Form 8-K - Current report - Item 3.01

—

Open source

Aug 12, 2024

8-K

Form 8-K - Current report - Item 2.02 Item 9.01

—

Open source

Jul 18, 2024

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Jun 10, 2024

8-K

Form 8-K - Current report - Item 5.07

—

Open source

May 24, 2024

8-K

Form 8-K - Current report - Item 3.01

—

Open source

May 7, 2024

8-K

Form 8-K - Current report - Item 2.02 Item 9.01

—

Open source

Chardan Capital Reiterates Buy Rating on Gossamer Bio, Inc. (GOSS)

Chardan Capital Initiates Coverage on Gossamer Bio, Inc. (GOSS) with Buy

Gossamer Bio, Inc. (GOSS) Surges 5.7% on Heavy Volume

Featured By

Chardan Capital Reiterates Buy Rating on Gossamer Bio, Inc. (GOSS)

Chardan Capital Initiates Coverage on Gossamer Bio, Inc. (GOSS) with Buy

Gossamer Bio, Inc. (GOSS) Surges 5.7% on Heavy Volume